A study coordinated by Dr. Vicenta Llorente-Cortés, a researcher at the CSIC and CIBERCV, and Dr. Antonio Pérez, director of the endocrinology unit and a member of CIBERDEM at the Research Institute Sant Pau, reveals that newly diagnosed patients with type II diabetes have elevated levels of soluble LRP1 receptor (sLRP1) and decreased levels of atrial natriuretic peptide (ANP).
The article, published in the journal Frontiers in Endocrinology, was conducted by analyzing liquid biopsies from newly diagnosed type II diabetes patients, in which it was found that strict glycemic and metabolic control over 12 months normalizes the sLRP1/ANP ratio after a year of treatment, and therefore, this index could be a reliable marker of cardiometabolic function.
Dr. Llorente explains that these findings open the door to search for new ways to intervene and personalize treatment to reduce the risk of heart disease in people with diabetes. She explains that sLRP1 is a marker that has been associated with coronary artery disease or atherosclerosis and also cardiovascular risk. “In other words, people with higher levels of this marker in their blood have a higher cardiovascular risk.”
It is known that atrial natriuretic peptide is very high in the blood when there is a situation of cardiac damage. “But, in addition, when these levels are very low, there is usually a metabolic problem behind it. So, both people with diabetes and those who are obese have very low levels of this peptide.”
The study was conducted in newly diagnosed patients with type II diabetes, meaning they had not yet been treated with any medication for this condition. The blood of these individuals was analyzed, and they were followed up for a year, and it was found that intervention through lifestyle changes and pharmacological interventions indicated by their metabolic condition normalized the levels of these two molecules.
“These markers could be useful for non-invasively assessing cardiovascular risk as well as the effectiveness of different therapies indicated to improve metabolic control and cardiovascular risk in patients with type II diabetes.”
García E, Gil P, Miñambres I, Benitez-Amaro A, Rodríguez C, Claudi L, Julve J, Benitez S, Sánchez-Quesada JL, Rives J, Garcia-Moll X, Vilades D, Perez A, Llorente-Cortes V. Increïen sLRP1 i decreixen atrial natriurètic peptide plasma de nivells en els nous diagnosis T2DM pacients són normalitzats per optimització de glycemic control. Front Endocrinol (Lausanne). 2023 Aug 10;14:1236487. doi: 10.3389/fendo.2023.1236487. PMID: 37635956; PMCID: PMC10450024.
